Document:

EX-4.2

 Exhibit 4.2 

EXTENSION OF MATURITY DATE UNDER 

CONVERTIBLE NOTE PURCHASE AGREEMENT 

July 30, 2012 
 Reference
is made to that certain Convertible Note Purchase Agreement, dated as of July 27, 2010 (the “Agreement”), by and among GeNO LLC, a Delaware limited liability company (the “Company”), and the purchasers named on
the Schedule of Purchasers attached thereto (the “Purchasers”). Capitalized terms not defined herein have the meanings ascribed to them in the Agreement. 

WHEREAS, the Agreement provides that the Majority Note Holders may, by written consent, extend the Maturity Date; and 

WHEREAS, the undersigned, being Purchasers holding Notes representing more than fifty percent (50%) of the Total Committed Principal
Amount, are Majority Note Holders; 
 NOW, THEREFORE, the undersigned hereby consent to amend the definition of Maturity Date by changing
the reference to August 1, 2012 therein to February 1, 2013. Other than as amended hereby, the Agreement and the Notes issued thereunder shall remain in full force and effect. 

IN WITNESS WHEREOF, the parties have executed this Extension of Maturity Date Under Note Purchase Agreement as of the date first above
written. 
  

	
	PURCHASERS:
	
	   

 ACKNOWLEDGED AND ACCEPTED: 
  

					
	GENO LLC
		
	By:	 	 /s/ David Fine

		 	Name:	 	David Fine
		 	Title:	 	Chief Executive OfficerEX-4.3

 Exhibit 4.3 
 AMENDMENT TO CONVERTIBLE NOTE PURCHASE AGREEMENT 
 THIS AMENDMENT TO
CONVERTIBLE NOTE PURCHASE AGREEMENT (this “Amendment”) is made as of November 2, 2012, by and among GeNO LLC, a Delaware limited liability company (the “Company”), and the Purchasers named on the Schedule
of Purchasers attached to the Convertible Note Purchase Agreement dated July 27, 2010 by and among the Company and the Purchasers, as amended (the “Convertible Note Purchase Agreement”). 

WHEREAS, the Company and the Purchasers desire to amend the Convertible Note Purchase Agreement to modify the definition of New
Equity Share Price as used therein. 
 NOW, THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS: 

1. Definitions. As used in the Convertible Note Purchase Agreement, the term “New Equity Share Price” shall mean the lower of
(a) the price of Equity Securities issued to The Medicines Company pursuant to a license agreement, if any, entered into with the Company and (b) the price per share of the Equity Securities issued and sold to venture capital or other
financial institutional or strategic investors before the Maturity Date in the next New Equity Financing after the date of this Agreement. 
 2. All terms of the Convertible Note Purchase Agreement not modified by this Amendment shall remain in full force and effect. 
 IN WITNESS WHEREOF, the parties have executed this Amendment to Convertible Note Purchase Agreement as of the date first above written. 

 

			
	GENO LLC
		
	By:	 	/s/ David H. Fine
		 	David H. Fine
		 	Chief Executive Officer

 
	
	PURCHASERS:EX-4.4

 Exhibit 4.4 
 AMENDMENT TO 
 CONVERTIBLE NOTE PURCHASE AGREEMENT 

THIS AMENDMENT TO CONVERTIBLE NOTE PURCHASE AGREEMENT (this “Amendment”) is made as of January 29, 2013, by
and among GeNO LLC, a Delaware limited liability company (the “Company”), and the Purchasers named on the Schedule of Purchasers attached to the Convertible Note Purchase Agreement dated July 27, 2010 by and among the Company
and the Purchasers, as amended (the “Convertible Note Purchase Agreement”). 
 WHEREAS, the Company and
the Purchasers desire to amend the Convertible Note Purchase Agreement, 
 NOW, THEREFORE, THE PARTIES HEREBY AGREE AS
FOLLOWS: 
 1. The definition of Maturity Date in the Convertible Note Purchase Agreement is hereby amended to read in its
entirety as follows: 
 “Maturity Date” shall mean the earliest to occur of (i) the closing of a New Equity
Financing, Sale of the Company, or License transaction, or (ii) October 31, 2013, unless extended by written consent of the Majority Note Holders. 
 2. All terms of the Convertible Note Purchase Agreement not modified by this Amendment shall remain in full force and effect. 
 IN WITNESS WHEREOF, the parties have executed this Amendment to Convertible Note Purchase Agreement as of the date first above written. 

 

			
	GENO LLC
		
	By:	 	/s/ David H. Fine
		 	David H. Fine
		 	Chief Executive Officer

 
	
	PURCHASERS:EX-4.5

 Exhibit 4.5 

THIS NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“SECURITIES ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, OR AN OPINION OF COUNSEL SATISFACTORY TO THE
COMPANY THAT REGISTRATION IS NOT REQUIRED UNDER SUCH ACT OR UNLESS SOLD PURSUANT TO RULE 144 UNDER THE SECURITIES ACT. 
 CONVERTIBLE
PROMISSORY NOTE 
  

			
	 No. [    ]
	  	Date of Issuance
	 $[                    ].00
	  	July [    ], 2010

 FOR VALUE RECEIVED, GeNO, LLC, a Delaware limited liability company (the “Company”), hereby
promises to pay [                    ] (the “Holder”), the amounts advanced to the Company pursuant to this Note up to the principal
sum of [                    ] Dollars ($
[                    ].00), together with interest on the Outstanding Principal from the date of this Note. Interest shall accrue on Advances at the
rate of ten percent (10.0%) per annum, compounded annually, commencing from the date of an Advance. Unless earlier converted into Conversion Shares pursuant to Section 2.1 of that certain Convertible Note Purchase Agreement dated as of
July 27, 2010, by and among the Company, Holder and certain other parties (as such agreement may be amended, supplemented or otherwise modified from time to time, the “Purchase Agreement”), the Outstanding Loan Amount shall be
due and payable by the Company at the Maturity Date. This Note is one of a series of Notes issued pursuant to the Purchase Agreement, and capitalized terms not defined herein shall have the meaning set forth in the Purchase Agreement. 

1. Advances. Pursuant to Section 1.5 of the Purchase Agreement, the Company may at any time request the Holder to advance the
Purchaser’s Pro Rata Advance under this Note up to the Holder’s Committed Principal Amount. The Company shall update Schedule 1 to this Note to reflect the date and the amount of each Advance. Failure to make an Advance shall
result in the Holder forfeiting certain rights under this Note pursuant to Section 1.5 of the Purchase Agreement. 
 2. Payment.
All payments under this Note shall be made in lawful money of the United States of America at the principal office of the Company, or at such other place as the Holder hereof may from time to time designate in writing to the Company. Payment shall
be credited first to Costs (as defined below), if any, then to accrued interest due and payable and any remainder applied to Outstanding Principal. Prepayment of the Outstanding Loan Amount may not be made without the consent of the Majority Note
Holders; provided, however, that if at least ninety percent (90%) of the Outstanding Loan Amount has been prepaid in the form of cash or equity of the Company, the Company may prepay the remainder in cash without the consent of
the Majority Note Holders. The Company hereby waives demand, notice, presentment, protest and notice of dishonor. 

 3. Conversion of the Notes. This Note and any amounts due hereunder shall be convertible
into Conversion Shares in accordance with the terms of Section 2.1 of the Purchase Agreement. As promptly as practicable after the conversion of this Note, the Company at its expense shall issue and deliver to the Holder of this Note, upon
surrender of the Note, a certificate or certificates for the number of full Conversion Shares issuable upon such conversion. 
 4.
Amendments and Waivers; Resolutions of Dispute; Notice. The amendment or waiver of any term of this Note, the resolution of any controversy or claim arising out of or relating to this Note and the provision of notice shall be conducted
pursuant to the terms of the Purchase Agreement. 
 5. Successors and Assigns. This Note applies to, inures to the benefit of, and
binds the successors and assigns of the parties hereto; provided, however, that the Company may not assign its obligations under this Note without the written consent of the Majority Note Holders. Any transfer of this Note may be
effected only pursuant to the Purchase Agreement and by surrender of this Note to the Company and reissuance of a new note to the transferee. The Holder and any subsequent holder of this Note receives this Note subject to the foregoing terms and
conditions, and agrees to comply with the foregoing terms and conditions for the benefit of the Company and any other holders. 
 6.
Officers and Managers Not Liable. In no event shall any officer or manager of the Company be liable for any amounts due and payable pursuant to this Note. 

7. Expenses. The Company hereby agrees, subject only to any limitation imposed by applicable law, to pay all expenses, including
reasonable attorneys’ fees and legal expenses, incurred by the Holder of this Note (“Costs”) in endeavoring to collect any amounts payable hereunder which are not paid when due, whether by declaration or otherwise. The Company
agrees that any delay on the part of the Holder in exercising any rights hereunder will not operate as a waiver of such rights. The Holder of this Note shall not by any act, delay, omission or otherwise be deemed to have waived any of its rights or
remedies, and no waiver of any kind shall be valid unless in writing and signed by the party or parties waiving such rights or remedies. 

8. Governing Law. This Note shall be governed by and construed under the laws of the State of Delaware (excluding the laws and rules of
law applicable to conflicts or choice of law). 
  

			
	GENO LLC
		
	By:	 	  

	Name:	 	David Fine, Chief Executive Officer

  
 2 

 SCHEDULE 1 
  

					
	 Date of Advance
	 	 Amount of Advance
	 	 Company Acknowledgment

		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
		 		 	
	 TOTAL:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}]]